TATA HEALTH (01255) has announced its interim results for 2026, showing a revenue decline of 4.5% to HK$47.275 million compared to the previous period. The company reported a loss attributable to shareholders of HK$290,000, contrasting with a profit of HK$20.596 million in the same period last year.
The basic loss per share stood at HK$0.001. According to the company, the year-on-year decrease in revenue was mainly driven by reduced income from its footwear business in the Hong Kong and Macau regions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.